Association Between Polycystic Ovary Syndrome and the Polymorphisms of Aryl Hydrocarbon Receptor Repressor, Glutathione-S-transferase T1, and Glutathione-S-transferase M1 Genes

Abstract

Objective

To investigate the association between the aryl hydrocarbon receptor repressor (AhRR) C/G polymorphisms and glutathione-S-transferase M1 (GSTM1) and GSTT1 null mutation and the risk of polycystic ovary syndrome (PCOS) in Korean women.

Methods

This was a case–control study of 478 women with PCOS and 376 aged-matched healthy controls. Genotyping of the AhRR C/G polymorphism and GSTM1 and GSTT1 were performed using real-time PCR analysis and multiplex PCR, respectively.

Results

The genotype distribution of the AhRR C/G polymorphisms and GSTM1/GSTT1 null mutations did not differ between women with PCOS and controls. Using the wild-type combined AhRR CC and GSTT1 present genotype as a reference, the odds that a woman had PCOS were 1.54 (95% CIs 1.04–2.29) times higher if she had a combined AhRR CG or GG and GSTT1 null genotype. The odds that a woman had PCOS was 1.48 (95% CIs 1.08–2.04) times higher if she had a combined GSTM1/GSTT1 null genotype compared with the wild-type combined GSTM1/GSTT1 present genotype. However, there were no significant associations between the risk of PCOS and any combined AhRR and GSTM1.

Conclusions

Our data suggest that a combined AhRR CG or GG and GSTT1 null genotype or a combined GSTT1/GSTM1 null genotype might be associated with an increased risk of PCOS.

摘要

目标：探讨韩国女性芳香烃受体抑制因子(AhRR)C/G多态性、谷胱甘肽-S-转移酶M1(GSTM1)和GSTT1无效突变与多囊卵巢综合征(PCOS)发病风险之间的关系。

方法：这是一项病例对照研究, 纳入478名PCOS女性和376名年龄匹配的健康对照。AhRR C/G多态性和GSTM1、GSTT1基因分型分别采用实时荧光定量PCR和多重PCR进行分析。

结果：AhRR C/G多态性和GSTM1/GSTT1无效突变的基因分型其分布在PCOS组和对照组之间无明显差异。以野生型AhRR CC和GSTT1基因型为参照, AhRR CG或GG和GSTT1缺失基因型组合的女性患PCOS的几率是对照组的1.54倍(95% CIs为1.04∼2.29)。GSTM1/GSTT1缺失基因型组合的女性患PCOS的几率是表达野生型GSTM1/GSTT1基因型的1.48倍(95% CIs为1.08∼2.04)。然而, PCOS风险与AhRR和GSTM1组合之间没有显著关系。

结论：我们的数据表明, AhRR CG或GG和GSTT1缺失基因型组合或GSTT1/GSTM1缺失基因型组合可能与PCOS的风险增加相关。

Keywords:

• Aryl hydrocarbon receptor repressor
• endocrine disruptor
• glutathione-S-transferase polycystic ovary syndrome
• polymorphism

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This study was supported by a grant from the Seoul National University Hospital Research Fund [04-2017-0370].